Crop Life Science
Key Fundamentals
SMEFertilizers & AgrochemicalsChemicalsPrice-based figures as of · TTM
- ROCE
- 11.60%
- Debt to Equity
- 0.67
- EPS (TTM)
- —
- Book Value
- ₹49.15
- Market Cap
- —
- P/E (TTM)
- —
- P/B
- 1.87
- ROE
- 8.45%
- Dividend Yield
- 0.00%
- EBITDA
- ₹19.50 Cr
- 52W High
- ₹93.20
- 52W Low
- ₹39.05
- Day Range
- ₹92.00 – ₹92.00
- Volume
- 4,000
Peer Comparison
Commodities › Chemicals › Pesticides & Agrochemicals
| ₹529.00 | 22.09 | ₹43,728 Cr | 1.28 | 1.16% | 5.64% | 10.10% | ₹52,804 Cr | ₹2,323 Cr | |
| ₹2,187.00 | 28.48 | ₹33,248 Cr | 2.95 | 0.69% | 11.20% | 15.00% | ₹6,516 Cr | ₹1,164 Cr | |
| ₹328.10 | 28.24 | ₹15,980 Cr | 4.43 | 0.41% | 17.60% | 23.50% | ₹3,192 Cr | ₹581 Cr | |
| ₹3,249.90 | 19.95 | ₹14,602 Cr | 4.92 | 4.57% | 23.70% | 29.10% | ₹5,595 Cr | ₹733 Cr | |
| ₹677.95 | 9.77 | ₹6,015 Cr | 1.88 | 2.23% | 23.20% | 30.20% | ₹5,357 Cr | ₹626 Cr | |
| ₹942.75 | 15.83 | ₹4,217 Cr | 2.50 | 0.21% | 18.50% | 23.80% | ₹1,953 Cr | ₹268 Cr | |
| ₹189.67 | 17.23 | ₹3,734 Cr | 1.68 | 1.58% | 10.20% | 14.10% | ₹2,962 Cr | ₹214 Cr | |
| Crop Life Science (this company) | ₹92.00 | — | ₹159 Cr | 1.87 | 0.00% | 8.45% | 11.60% | — | — |
| Median 8 companies | ₹603.48 | 19.95 | ₹10,309 Cr | 2.19 | 0.93% | 14.40% | 19.25% | ₹5,357 Cr | ₹626 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 84/100
Category scores
- Quality
- 52
- Average
- Returns, margins, earnings quality 22% weight
- Valuation
- 43
- Weak
- Cheap vs sector & own history 24% weight
- Growth
- 39
- Weak
- Sales & profit trajectory 9% weight
- Financial Health
- 32
- Poor
- Solvency, leverage, coverage 9% weight
- Momentum
- 99
- Strong
- Trend strength, vol-adjusted 12% weight
- Ownership
- 38
- Weak
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
No strengths listed
Weaknesses
3- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -2.80%
- Company has a low return on equity of 9.02% over last 3 years.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 5 | 1 | 13 |
| Oscillators | Strong Bearish | 5 | 1 | 3 |
| Moving Averages | Strong Bullish | 0 | 0 | 10 |
Oscillators
Strong Bearish
Overall
Strong Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 75.43
- Bearish
- MACD (12,26,9)
- 5.13
- Bullish
- SMA (50)
- 75.48
- Bullish
- SMA (200)
- 56.44
- Bullish
As of
Growth Rate
From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.
Revenue
| 5Y | +13.66% |
|---|---|
| 3Y | +16.02% |
| 1Y | +3.57% |
Net profit
| 5Y | +11.84% |
|---|---|
| 3Y | +20.51% |
| 1Y | 0.00% |
Operating cash flow
| 5Y | Turned negative |
|---|---|
| 3Y | Turned negative |
| 1Y | Outflow widened by ₹6 Cr |
Operating margin· change in pp
| 5Y | −0.04 pp |
|---|---|
| 3Y | −0.86 pp |
| 1Y | +0.21 pp |
Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.
Revenue by year
| Mar 2020 | ₹126 Cr |
|---|---|
| Mar 2021 | ₹107 Cr |
| Mar 2022 | ₹94.00 Cr |
| Mar 2023 | ₹130 Cr |
| Mar 2024 | ₹191 Cr |
| Mar 2025 | ₹196 Cr |
| Mar 2026 | ₹203 Cr |
Net profit by year
| Mar 2020 | ₹3.00 Cr |
|---|---|
| Mar 2021 | ₹4.00 Cr |
| Mar 2022 | ₹3.00 Cr |
| Mar 2023 | ₹4.00 Cr |
| Mar 2024 | ₹6.00 Cr |
| Mar 2025 | ₹7.00 Cr |
| Mar 2026 | ₹7.00 Cr |
Half-yearly Results
₹ Cr| Particulars | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 79 | 52 | 97 | 101 | 106 | 94 | 120 | 87 |
| Expenses | 75 | 45 | 91 | 95 | 98 | 87 | 112 | 78 |
| Operating Profit | 5 | 7 | 6 | 6 | 8 | 8 | 8 | 9 |
| OPM % | 6% | 13% | 7% | 6% | 8% | 8% | 7% | 10% |
| Other Income | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 |
| Interest | 1 | 2 | 1 | 2 | 2 | 2 | 3 | 3 |
| Depreciation | 1 | 3 | 2 | 2 | 2 | 2 | 2 | 2 |
| PBT | 2 | 3 | 4 | 4 | 4 | 5 | 4 | 6 |
| Tax % | 62% | −1% | 20% | 32% | 23% | 30% | 26% | 32% |
| Net Profit | 1 | 3 | 3 | 3 | 3 | 3 | 3 | 4 |
| EPS (₹) | 0.78 | 2.61 | 1.96 | 1.56 | 2.01 | 1.86 | 1.88 | 2.19 |
Profit & Loss
₹ Cr| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 126 | 107 | 94 | 130 | 191 | 196 | 203 |
| Expenses | 118 | 98 | 86 | 118 | 178 | 180 | 186 |
| Operating Profit | 8 | 9 | 8 | 12 | 13 | 16 | 17 |
| OPM % | 7% | 8% | 8% | 9% | 7% | 8% | 8% |
| Other Income | 0 | 1 | 0 | 1 | 2 | 1 | 2 |
| Interest | 2 | 2 | 2 | 3 | 3 | 5 | 5 |
| Depreciation | 2 | 3 | 2 | 4 | 3 | 3 | 3 |
| PBT | 5 | 5 | 4 | 6 | 8 | 9 | 10 |
| Tax % | 30% | 25% | 25% | 27% | 26% | 26% | 29% |
| Net Profit | 3 | 4 | 3 | 4 | 6 | 7 | 7 |
| EPS (₹) | 2.69 | 3.08 | 2.34 | 3.39 | 3.52 | 3.86 | 4.08 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
₹ Cr| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 12 | 12 | 12 | 12 | 17 | 17 | 17 |
| Reserves | 18 | 21 | 24 | 29 | 55 | 61 | 68 |
| Borrowings | 16 | 18 | 22 | 27 | 34 | 44 | 57 |
| Other Liabilities | 31 | 35 | 37 | 34 | 67 | 55 | 63 |
| Total Liabilities | 76 | 86 | 95 | 102 | 172 | 178 | 205 |
| Fixed Assets | 12 | 13 | 11 | 16 | 22 | 22 | 16 |
| CWIP | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 12 | 13 | 13 |
| Other Assets | 64 | 73 | 82 | 86 | 138 | 142 | 177 |
| Total Assets | 76 | 86 | 95 | 102 | 172 | 178 | 205 |
Cash Flow
₹ Cr| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating | 3 | 4 | 0 | 2 | −8 | −2 | −8 |
| Investing | −1 | −2 | −2 | −4 | −16 | −4 | 2 |
| Financing | −3 | −1 | 1 | 1 | 24 | −5 | −9 |
| Net Cash Flow | −1 | 1 | −1 | −2 | 0 | −11 | −15 |
| Free Cash Flow | 2 | 1 | −2 | −3 | −13 | −5 | −4 |
| CFO/EBITDA | 46 | 58 | 11 | 34 | −49 | 3 | −31 |
Ratios
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 80 | 89 | 143 | 92 | 148 | 129 | 134 |
| Inventory Days | 93 | 159 | 137 | 104 | 99 | 126 | 170 |
| Days Payable | 72 | 108 | 137 | 79 | 131 | 113 | 127 |
| Cash Conversion Cycle | 100 | 140 | 143 | 116 | 117 | 141 | 177 |
| Working Capital Days | 50 | 74 | 93 | 86 | 86 | 89 | 105 |
| ROCE % | — | 14% | 11% | 14% | 13% | 12% | 12% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Crop Life Science insights
60 extracted metrics across FY20–FY26.
Documents
- 10 Oct 2026
- 10 Oct 2026
- 10 Oct 2026
- 10 Oct 2026
Frequently Asked Questions about Crop Life Science
What does Crop Life Science Ltd do?
Where is Crop Life Science Ltd (CLSL) listed?
Which sector does Crop Life Science Ltd belong to?
What is the 52-week high and low of Crop Life Science Ltd?
What is the Return on Equity (ROE) of Crop Life Science Ltd?
Company Information
Incorporated in 2006, Crop Life Sciences Ltd manufactures and deals in pesticides, insecticides, herbicide, fertilizers and allied products related to research and technical formulations
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/CLSL.md for Crop Life Science Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.